Department of Urology, Cardarelli Hospital, Campobasso, Italy.
Lab Experimental Oncology, Department of Biology, University of Tor Vergata, 00133, Rome, Italy.
Amino Acids. 2020 Mar;52(3):445-451. doi: 10.1007/s00726-020-02822-7. Epub 2020 Feb 7.
Weight loss in patients with cancer is caused by cancer cachexia and chemotherapy-induced nausea and vomiting. Recent developments in antiemetic drugs have substantially improved nausea and vomiting, but this intervention did not reduce weight loss and other more severe side effects of chemotherapy, like anorexia, weakness, cough, dyspnea, hemoptysis, and pain. This study aimed to investigate the effects of nutrition intervention with a food supplement, during chemotherapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Patients received individualized nutrition counseling by a registered dietitian and were provided with oral supplements of Texidrofolico for 90 days. Bodyweight and the mentioned other side effects were evaluated at baseline and after 90 days of intervention. To assess the effects of this dietary supplement, a total of 30 patients were retrospectively enrolled as controls, and the bodyweight and change in side effects of chemotherapy were compared with those observed in 30 Texidrofolico-treated patients. After 90-day intervention, by oral supplement of Texidrofolico, the patients, during the course of cytotoxic chemotherapy, showed an improved quality of life and not significant weight and BMI loss respect the control group. Furthermore, the number of patients, treated with Texidrofolico who maintained or increased their body weight, after 90 days of treatment was significantly higher than in the control group. The effects of treatment with the food supplement have also been studied from a metabolic point of view. It was possible to find that one of the known markers of tumor growth, plasma polyamines, was reduced after the treatment. A possible relationship between these biogenic amines and the folate cycle is discussed. In conclusion, early intensive nutrition intervention with oral supplements of Texidrofolico during chemotherapy of NSCLC patients prevents weight loss and it is beneficial for their quality of life.
癌症患者的体重减轻是由癌性恶病质和化疗引起的恶心和呕吐引起的。止吐药物的最新进展极大地改善了恶心和呕吐，但这种干预措施并没有减轻体重减轻和化疗的其他更严重的副作用，如厌食、乏力、咳嗽、呼吸困难、咯血和疼痛。本研究旨在探讨在晚期非鳞状非小细胞肺癌（NSCLC）患者化疗期间进行营养干预（补充食品）的效果。患者接受注册营养师的个性化营养咨询，并在 90 天内口服 Texidrofolico 补充剂。在基线和干预 90 天后评估体重和上述其他化疗副作用。为了评估这种膳食补充剂的效果，共回顾性纳入 30 名作为对照的患者，比较了 Texidrofolico 治疗患者的体重和化疗副作用变化与观察到的体重和化疗副作用变化。经过 90 天的干预，通过口服 Texidrofolico 补充剂，在细胞毒性化疗过程中，患者的生活质量得到改善，与对照组相比，体重和 BMI 无明显减轻。此外，在 90 天的治疗后，使用 Texidrofolico 治疗并维持或增加体重的患者数量明显高于对照组。还从代谢的角度研究了食物补充剂的治疗效果。结果发现，已知的肿瘤生长标志物之一，血浆多胺，在治疗后减少。讨论了这些生物胺与叶酸循环之间的可能关系。总之，在 NSCLC 患者化疗期间进行早期强化营养干预（口服 Texidrofolico 补充剂）可预防体重减轻，有益于患者的生活质量。
